Literature DB >> 642401

Anti-HBc, HBeAg and DNApolymerase activity in healthy HBsAg carriers and patients with inflammatory liver diseases.

W Arnold, G Hess, R H Purcell, P M Kaplan, J L Gerin, K H Meyer.   

Abstract

In this paper we report on anti-HBc-titers, HBcAg, DNApolymerase activity in the serum and intracellular HBsAg in healthy HBsAg-carriers and patients with HBsAg-positive inflammatory liver diseases. 32/44 patients with acure virus-B-hepatitis were negative for anti-HBc in the first week of the disease. Anti-HBc-titers in healthy HBsAg-carriers varied between 1:10 and 1:32,000 (medium titer 1:4,000). In HBsAg-positive CAH we found a medium titer between 1:32,000 and 1:64,000, in cases with CPH of about 1:16,000. All autoimmune type CAH showed anti-HBc-titers less than 1:10. By immunofluorescence we could demonstrate in a group of 71 asymptomatic HBsAg-carriers in none of the healthy HBsAg-carriers HBcAg in the liver cell nuclei. In contrast HBcAg could only be found in 4/5 HBsAg positive CAH- and 6/9 CPH patients. No elevated DNApolymerase activity could be demonstrated in healthy HBsAg-carriers. Out of 44 patients with virus-B-hepatitis only 3 showed elevated DNApolymerase activity. On the other hand DNApolymerase elevation was demonstrable in 17/37 cases with CAH and 9/15 with CPH. The investigations showed a strong correlation between the demonstration of HBcAg in the serum and the DNApolymerase activity. The characteristic findings enabled us to differentiate between "healthy" HBsAg-carriers and HBsAg-carriers with inflammatory liver diseases.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 642401     DOI: 10.1007/BF01489176

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  37 in total

1.  Studies on the development and persistence of complement-fixing and neutralizing antibodies in human poliomyelitis.

Authors:  E H LENNETTE; N J SCHMIDT
Journal:  Am J Hyg       Date:  1957-03

2.  Changes in the solubility of immunoglobulins after fluorescent labeling and its influence on immunofluorescent techniques.

Authors:  W Arnold; H von Mayersbach
Journal:  J Histochem Cytochem       Date:  1972-12       Impact factor: 2.479

3.  New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants.

Authors:  L O Magnius; J A Espmark
Journal:  J Immunol       Date:  1972-11       Impact factor: 5.422

4.  DNA of a human hepatitis B virus candidate.

Authors:  W S Robinson; D A Clayton; R L Greenman
Journal:  J Virol       Date:  1974-08       Impact factor: 5.103

5.  Association of dane particles with e antigen in the serum of asymptomatic carriers of hepatitis B surface antigen.

Authors:  K Takahashi; M Imai; F Tsuda; T Takahashi; Y Miyakawa
Journal:  J Immunol       Date:  1976-07       Impact factor: 5.422

6.  A new antigen complex co-occurring with Australia antigen.

Authors:  L O Magnius; A Espmark
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1972

7.  e Antigen-antibody system as indicator of liver damage in patients with hepatitis-B antigen.

Authors:  N El Sheikh; I L Woolf; R M Galbraith; A L Eddleston; I W Dymock; R Williams
Journal:  Br Med J       Date:  1975-11-01

8.  Hepatitis B-specific DNA polymerase activity during post-transfusion hepatitis.

Authors:  P M Kaplan; J L Gerin; H J Alter
Journal:  Nature       Date:  1974-06-21       Impact factor: 49.962

9.  Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure.

Authors:  H J Alter; L B Seeff; P M Kaplan; V J McAuliffe; E C Wright; J L Gerin; R H Purcell; P V Holland; H J Zimmerman
Journal:  N Engl J Med       Date:  1976-10-21       Impact factor: 91.245

10.  [The characterization of clinically healthy hepatitis-b-surface-antigen (HBsAg)-carriers. Clinical, biochemical, histiological and immunological investigations in 129 case of a prospective study (author's transl)].

Authors:  J Knolle; M Born; G Hess; O Klinge; W Arnold; H Bitz; K H Meyer
Journal:  Klin Wochenschr       Date:  1976-06-15
View more
  7 in total

1.  Radioimmunoassay in the detection of the hepatitis B e antigen/antibody system in asymptomatic carriers of hepatitis B surface antigen. Correlation with serum Dane particle associated DNA polymerase activity.

Authors:  G Pastore; A R Zanetti; P Ferroni; P Dentico; G Angarano; O Schiraldi
Journal:  Infection       Date:  1979       Impact factor: 3.553

2.  The significance of the HBeAg/anti-HBe system in hemodialysis patients. A multicenter study.

Authors:  F Fiaccadori; S David; G Faggion; N Feriani; C Ferrari; V Franco; T Giuberti; C Grutta D'Auria; G La Greca; G Magnani
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

3.  Quantitation of HBeAG and anti-HBe by RIA in sera of chronic HBsAG carriers and individuals with type B hepatitis.

Authors:  W Arnold; G Hess; H Kawakami; K H Meyer zum Büschenfelde
Journal:  Klin Wochenschr       Date:  1981-06-15

4.  IgM antibody to hepatitis B core antigen (anti-HBc IgM) in "healthy" HBsAg carriers: a longitudinal study of 75 cases.

Authors:  H H Dromeyer; W Arnold; P Kryger; J O Nielsen; K H Meyer zum Büschenfelde
Journal:  Klin Wochenschr       Date:  1981-06-15

5.  Comparison of indicators for dane particles.

Authors:  G Hess; W Arnold; K H Meyer zum Buschenfelde
Journal:  Klin Wochenschr       Date:  1980-04-01

6.  [Spread of hepatitis B virus infection among family contacts of asymptomatic HBsAg carriers (author's transl)].

Authors:  H H Dormeyer; G Hess; M Born; H Schönborn; W Arnold; J Knolle; B Zöller
Journal:  Klin Wochenschr       Date:  1979-12-03

7.  Clinically important immunological processes in acute and fulminant hepatitis, mainly due to hepatitis B virus.

Authors:  M K Mackenjee; P Kiepiela; R Cooper; H M Coovadia
Journal:  Arch Dis Child       Date:  1982-04       Impact factor: 3.791

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.